159 related articles for article (PubMed ID: 18400964)
1. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.
Spinowitz B; Germain M; Benz R; Wolfson M; McGowan T; Tang KL; Kamin M;
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1015-21. PubMed ID: 18400964
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.
Pergola PE; Gartenberg G; Fu M; Sun S; Wolfson M; Bowers P
Clin J Am Soc Nephrol; 2010 Apr; 5(4):598-606. PubMed ID: 20185602
[TBL] [Abstract][Full Text] [Related]
3. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.
McGowan T; Vaccaro NM; Beaver JS; Massarella J; Wolfson M
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1006-14. PubMed ID: 18417741
[TBL] [Abstract][Full Text] [Related]
5. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.
Pergola PE; Gartenberg G; Fu M; Wolfson M; Rao S; Bowers P
Clin J Am Soc Nephrol; 2009 Nov; 4(11):1731-40. PubMed ID: 19808215
[TBL] [Abstract][Full Text] [Related]
7. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease.
Provenzano R; Singh AK
Endocr Pract; 2007; 13(3):251-9. PubMed ID: 17599856
[TBL] [Abstract][Full Text] [Related]
8. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
10. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
11. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
[TBL] [Abstract][Full Text] [Related]
12. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease.
Benz R; Schmidt R; Kelly K; Wolfson M
Clin J Am Soc Nephrol; 2007 Mar; 2(2):215-21. PubMed ID: 17699416
[TBL] [Abstract][Full Text] [Related]
13. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
14. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
Schwartzberg L; Burkes R; Mirtsching B; Rearden T; Silberstein P; Yee L; Inamoto A; Lillie T
BMC Cancer; 2010 Oct; 10():581. PubMed ID: 20973982
[TBL] [Abstract][Full Text] [Related]
15. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and treatment of anemia with once-weekly epoetin alfa in patients with diabetes and chronic kidney disease.
Lorber DL; Provenzano R; McClellan W
Endocr Pract; 2006; 12(5):506-13. PubMed ID: 17002925
[TBL] [Abstract][Full Text] [Related]
17. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
19. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]